Featured Research

from universities, journals, and other organizations

Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?

Date:
April 15, 2013
Source:
Helsingin yliopisto (University of Helsinki)
Summary:
Adenosine-5’-triphosphate (ATP) is the main energy source for all forms of work inside our cells. Scientists have found that even a short-term shortage of ATP supply can be fatal for cancer cells because activation of a mitochondria-addressed cell death pathway. These findings may lead to new therapies specifically targeting the altered energy supply chains of cancer cells to get cancer cells to commit suicide.

Scientists have discovered that low levels of ATP make cancer gene expressing cells suicidal. Declining ATP levels activate a cellular energy sensor AMPK, which adds a phosphate group to tumor suppressor protein p53, extending the protein's lifetime. This form of p53 moves to mitochondria to activate a cell death protein Bak, which renders cells sensitive to apoptosis. In this immunofluorescence microscope image of cancer gene Myc expressing cells, active death protein Bak appears as green spots localizing on the surface of the mitochondria. The blue staining marks the cell nuclei.
Credit: Juha Klefstrom Research Group / University of Helsinki

Adenosine-5’-triphosphate (ATP) is the main energy source for all forms of work inside our cells. Scientists from the University of Helsinki, Finland have found that even a short-term shortage of ATP supply can be fatal for cancer cells because activation of a mitochondria-addressed cell death pathway. These findings may lead to new therapies specifically targeting the altered energy supply chains of cancer cells to get cancer cells to commit suicide.

ATP is the main energy currency of cells and one might expect that not only contracting muscle, but also uncontrollably dividing cancer cells would have a high demand for ATP. However, for some reason cancer cells have re-programmed their metabolic engines to produce less ATP. The phenomenon, known as Warburg effect, is typical for cancer cells and the mechanism behind is believed to benefit cancer cells by switching biochemical engines from energy manufacturing reactions to anabolic reactions, which primarily support growth of the cell size and proliferation.

The triggers for “non-stop” proliferation programs in cancer cells are the tumor-promoting oncoproteins, like protein called Myc. Luckily, it seems that oncoproteins are not perfect programmers.

Finnish scientists from the University of Helsinki, investigating how Myc re-engineers metabolic pathways in cells, have identified an unexpected branch in the pathway - a branch that ends to cell death (apoptosis). The researchers found that Myc activates cancer-like changes in cell metabolism, causing a sudden fall in ATP concentration inside the cells. Declining ATP levels awake a bioenergy sensor protein known as AMP kinase (AMPK), which starts a biochemical chain of events moving a tumor suppressor protein p53 to the surface of the mitochondria. At mitochondria, p53 activates apoptosis-promoting proteins, the investigation suggests.

According to University of Helsinki scientist and Finnish Academy Research Fellow Juha Klefström, PhD, who led the study, “Myc oncoprotein not only boosts tumor cell proliferation but it also makes the cells vulnerable to cell suicide program, apoptosis. The cancer gene dependent vulnerability to apoptosis has promise to be the prime target for future targeted cancer therapies but first, we need to understand the cell pathways that are causing this vulnerability. The investigated connections between Myc, energy metabolism and apoptosis will help us to understand the biochemistry of cancer cell apoptosis. However, the finding is also interesting from a therapeutic standpoint since there are many drug-like molecules that can be used to turn on and off the AMPK controlled pathways in cancer cells.”

Healthy cells may encounter ATP and energy shortage for example, during strenuous exercise, so that alone is not sufficient to kill the cells. Why then Myc oncoprotein transformed cells succumb to ATP deprivation?

A graduate student Anni Nieminen, the first author in the study explains, “In healthy cells dwindling ATP levels signals activation of AMPK, which tells the cells to save energy, for example, by stopping the cell proliferation. The resting cells can then restock ATP supplies before entering the energy consuming proliferation again. However, cells with active Myc cannot stop the cell cycle engine and we think that the non-stop proliferation of the cells with low ATP content leads to prolonged activation of AMPK and p53. Gradual increase of p53 levels activates apoptosis promoting protein Bak on the surface of the mitochondria making these cells vulnerable to death. The inability of Myc transformed cells to rest and recover could explain why Myc makes cells so vulnerable to apoptosis.”

 How can these cancer cell specific metabolic pathways and reactions be targeted with drugs?

According to Juha Klefström, “For example, recent epidemiological studies have shown that a diabetes drug metformin, which acts as an AMPK activator, may reduce the risk of cancer. It is often claimed that a drug-induced AMPK activation starves cancer cells to death. Our study suggests that AMPK can speak directly to the cells’ death machinery, which opens new possibilities to exploit the AMPK pathway for cancer therapy.”   


Story Source:

The above story is based on materials provided by Helsingin yliopisto (University of Helsinki). Note: Materials may be edited for content and length.


Journal Reference:

  1. Anni I. Nieminen, Vilja M. Eskelinen, Heidi M. Haikala, Topi A. Tervonen, Yan Yan, Johanna I. Partanen, and Juha Klefström. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. PNAS, April 15, 2013 DOI: 10.1073/pnas.1208530110

Cite This Page:

Helsingin yliopisto (University of Helsinki). "Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?." ScienceDaily. ScienceDaily, 15 April 2013. <www.sciencedaily.com/releases/2013/04/130415172228.htm>.
Helsingin yliopisto (University of Helsinki). (2013, April 15). Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/04/130415172228.htm
Helsingin yliopisto (University of Helsinki). "Cancer cell metabolism kills: Possible new therapies targeting energy supply of cancer cells?." ScienceDaily. www.sciencedaily.com/releases/2013/04/130415172228.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins